Sex Hormones and Anticancer Immunity.

Details

Ressource 1Download: 30890551_AuthorManuscript.pdf (629.04 [Ko])
State: Public
Version: Author's accepted manuscript
License: All rights reserved
Serval ID
serval:BIB_2A2BB09AAB25
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Sex Hormones and Anticancer Immunity.
Journal
Clinical cancer research
Author(s)
Özdemir B.C., Dotto G.P.
ISSN
1078-0432 (Print)
ISSN-L
1078-0432
Publication state
Published
Issued date
01/08/2019
Peer-reviewed
Oui
Volume
25
Number
15
Pages
4603-4610
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Abstract
The impact of sex hormones on anticancer immunity deserves attention due to the importance of the immune system in cancer therapy and the recognition of sex differences in immunity. Cancer is ultimately the result of failed immune surveillance, and the diverging effects of male and female sex hormones on anticancer immunity could contribute to the higher cancer incidence and poorer outcome in men. Estrogens and androgens affect the number and function of immune cells, an effect that depends on cell type, tumor microenvironment, and the age and reproductive status of the individual. Despite the recent progress in immuno-oncology, our current understanding of the interplay between sex hormones and anticancer immune responses is in its infancy. In this review, we will focus on the impact of sex hormones on anticancer immunity and immunotherapy. We will discuss the potential role of the changing hormone levels in anticancer immunity during aging and in the context of menopausal hormone therapies and oral contraception. We will review emerging data on sex differences in PD-L1 expression and potential biomarkers predictive for the efficacy of immune checkpoint inhibitors such as the microbiome and consider ongoing clinical trials evaluating the potential impact of hormone deprivation therapies to increase response to immune checkpoint inhibitors in breast and prostate cancer. Finally, we will point to areas of future research.
Pubmed
Web of science
Create date
10/04/2019 16:08
Last modification date
20/09/2020 5:27
Usage data